Licensing status

Publication and contact information

Cardiovascular disease


Potassium channel Kv11.1 (KCNH2; hERG)

High throughput screening and rabbit studies identified a modulator of ERG activity that could help prevent drug-induced arrhythmias. In rabbits, pretreatment with the lead hit decreased the incidence of Tikosyn dofetilide-induced arrhythmias compared with no treatment. Next steps could include evaluating the compound in combination with other arrhythmogenic drugs.
Tikosyn, a selective potassium channel blocker from Pfizer Inc. is marketed to maintain normal sinus rhythm in patients with atrial fibrillation and/or atrial flutter arrhythmias.

SciBX 5(41); doi:10.1038/scibx.2012.1083
Published online Oct. 18, 2012

Patent and licensing status unavailable

Potet, F. et al. J. Biol. Chem.; published online Oct. 2, 2012;
Contact: Sabina Kupershmidt, Vanderbilt University School of Medicine, Nashville, Tenn.